Acorda Therapeutics, Inc.
- Jurisdiction
United States - LEI
5493007NPB5YRM8QGL53 - ISIN
US00484M7002 (ACOR )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€98.66M - Gross margin
79.7% - EBIT
-€20.73M - EBIT margin
-21.0% - Net income
-€224.69M - Net margin
-227.8%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: November 13, 2023